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ABSTRACT
Introduction Rheumatoid arthritis (RA) patients can be
classiﬁed based on presence or absence of anticitrullinated
peptide antibodies (ACPA) in their serum. This heterogeneity
among patients may reﬂect important biological differences
underlying the disease process. To date, the majority of
genetic studies have focused on the ACPA-positive group.
Therefore, our goal was to analyse the genetic risk factors
that contribute to ACPA-negative RA.
Methods We performed a large-scale genome-wide
association study (GWAS) in three Caucasian European
cohorts comprising 1148 ACPA-negative RA patients and
6008 controls. All patients were screened using the Illumina
Human Cyto-12 chip, and controls were genotyped using
different genome-wide platforms. Population-independent
analyses were carried out by means of logistic regression.
Meta-analysis with previously published data was performed
as follow-up for selected signals (reaching a total of 1922
ACPA-negative RA patients and 7087 controls). Imputation
of classical HLA alleles, amino acid residues and single
nucleotide polymorphisms was undertaken.
Results The combined analysis of the studied cohorts
resulted in identiﬁcation of a peak of association in the HLA-
region and several suggestive non-HLA associations. Meta-
analysis with previous reports conﬁrmed the association of
the HLA region with this subset and an observed association
in the CLYBL locus remained suggestive. The imputation and
deep interrogation of the HLA region led to identiﬁcation of
a two amino acid model (HLA-B at position 9 and HLA-
DRB1 at position 11) that accounted for the observed
genome-wide associations in this region.
Conclusions Our study shed light on the inﬂuence of the
HLA region in ACPA-negative RA and identiﬁed a suggestive
risk locus for this condition.
INTRODUCTION
Rheumatoid arthritis (RA) is a common auto-
immune disease that is associated with a progressive
loss of the joints induced by a chronic inﬂammation
of the joint synovium.1 In this inﬂammatory envir-
onment, different products of cell apoptosis and
necrosis accumulate, and citrullinated proteins can
be detected.2 The production of anticitrullinated
peptide/protein antibodies (ACPA) is a common but
not essential characteristic of RA patients, which is
thought to be inﬂuenced by the genetic back-
ground. Indeed, a strong correlation exists between
ACPA and alleles of the HLA-DRB1 gene at
chromosome 6 known as the shared epitope
(SE).3 4 Hence, the presence or absence of ACPA
divides RA patients into two serological and clinical
subgroups, ACPA positive (ACPA+) and ACPA
negative (ACPA−) RA.
ACPA are highly speciﬁc for RA and appear years
before the ﬁrst clinical manifestation of RA.5
Moreover, a number of studies have shown that
ACPA+ patients suffer more aggressive radiological
joint damage.6–9 It is worth mentioning that, the
most recent RA diagnostic criteria proposed by the
American College of Rheumatology (ACR) includes
ACPA among the classiﬁcation factors.10
Remarkably, different studies suggested the exist-
ence of a partial genetic overlap between the ACPA−
and the ACPA+ phenotypes, but evidence supporting
important genetic differences is increasing.11 In line
with this, a study by Viatte et al12 reported that the
SE, a HLA-DRB1*0401 tag-single nucleotide poly-
morphism (SNP) and variants located in TNFAIP3,
GIN1/C5orf30, STAT4, ANKRD55/ IL6ST, BLK and
PTPN22 showed signiﬁcant associations with ACPA−
RA patients. However, several RA susceptibility
factors showed no association with the ACPA−
subset, and those shared independently of the sero-
type revealed different strength of association and
effect size. Two high-throughput genotyping efforts,
a genome-wide association study (GWAS) and a
SNP-dedicated Immunochip-based dense mapping,
including ACPA− RA patients have been recently
carried out. The GWAS focused on the genetic
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comparison of both serological RA subgroups.13 Although no
genome-wide level association with the ACPA− subset was
described, signiﬁcant differences between ACPA+ and ACPA−
patients in the HLA region were apparent13 The Immunochip
approach revealed genome-wide level associations in the HLA
region and the ANKRD55 locus with ACPA− RA, and supported
differences with the ACPA+ subgroup in several loci.14
Additionally, a few loci have been associated with ACPA− RA but
not with ACPA+ RA, such as CLEC16A and IRF5 that have been
found following a candidate gene strategy.15 16 In spite of the
increasing interest in the identiﬁcation of genetic risk factors asso-
ciated with ACPA− RA, the underlying genetic background in this
subset of RA patients remains widely unknown.17
The aim of this study was to identify novel susceptibility loci
implicated in ACPA− RA susceptibility through a hypothesis-free
GWA strategy. Therefore, we carried out a genome-wide com-
bined analysis of three independent Caucasian European
cohorts, and a follow-up phase using a previously studied
GWAS cohort, comprising a total of 1922 ACPA− RA patients
and 7087 unaffected controls.
PATIENTS AND METHODS
Populations
All RA patients participating in this study met the 1987 ACR
criteria for the classiﬁcation of RA and were classiﬁed as ACPA−
using standard methods as described elsewhere.13 18 Control
populations comprised unaffected unrelated individuals from
the same geographical and ethnical origin as cases. All indivi-
duals in this study were of European ancestry (self-reported
and/or principal component analysis (PCA) derived, ﬁgure 1).
This study was approved by the local ethics committees of the
participating hospitals and all participating individuals gave
written informed consent. A description of the analysed popula-
tions is provided in online supplementary note 1.
The power to detect an association with an OR of 1.40 con-
sidering 1922 cases and 7087 controls, at the p value <5×10−8
level, under an additive model and using a minor allele fre-
quency (MAF) of 0.20 was of 96% (additional power calcula-
tions are provided in online supplementary table S1). For power
estimation we used Power Calculator for Genome Wide
Studies.19
Genotyping and imputation
The genotyping platforms for The Netherlands I, The
Netherlands II and Spain cohorts are described in table 1.
Quality control (QC) and imputation was conducted separately
for each cohort and each chip type, using a common approach
for all datasets (details in online supplementary note 2) using
PLINK.20 The Swedish cohort genotyping and QC were per-
formed as described in Padyukov et al.13
After QC, a total of 452 367 genotyped or imputed SNPs
were shared between The Netherlands I, The Netherlands II
and the Spanish case-control series; and 363 330 genotyped or
imputed SNPs were shared between the previously mentioned
cohorts and the Swedish population in Padyukov et al.13
All SNP genotypes in the HLA region (chromosome 6
between the positions 29 000 000 and 34 000 000 reaching a
total of 3882 SNPs) underwent a speciﬁc HLA imputation
process as described in previous reports.21–23 This novel
approach resulted in the imputation of classical HLA genotypes
(HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1,
HLA-DQA1, HLA-DQB1 and HLA-DRB1), their corresponding
amino acid sequences and SNPs (see online supplementary note
3 and table S2).21 23
STATISTICAL METHODS
The association of the imputed set of SNPs with ACPA− RA was
tested by logistic regression, and this approach was followed
Figure 1 Principal component
analysis (PCA) plot of the analysed
European populations. (A) The
Netherlands I versus The Netherlands II
populations PC1 versus PC3 plot; (B)
The Netherlands I population PC1
versus PC2; (C) The Netherlands II
population PC1 versus PC2; (D)
Spanish population PC1 versus PC2
population.
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separately in each cohort using PLINK (Genomic inﬂation
factors are shown in online supplementary note 4 and quantile-
quantile (QQ) plots in supplementary ﬁgure S1). We carried out
individual population PCA using EIGENSTRAT software in
order to detect population substructure.24 25 Then, the associ-
ation analyses for The Netherlands I, The Netherlands II and
Spain cohorts were adjusted for population substructure by
including the ﬁrst 10 PCs of each population as covariates in the
logistic regression (λThe Netherlands I=1.07; λThe Netherlands
II=1.02; λSpain=1.07; see online supplementary ﬁgure S1).
A combined analysis using the inverse variance method under
a ﬁxed effects model was performed on the basis of the
PCA-adjusted association results of The Netherlands I, The
Netherlands II and Spain cohorts using PLINK. The inﬂation
value for this analysis was λ=1.02. Heterogeneity across the
datasets was evaluated using Cochran’s Q test, and those loci
showing a high heterogeneity (Q<0.05) were not considered
for the validation step.
Non-HLA SNPs and showing a signiﬁcant p value at a tier 2
association level (p<5×10−5) in the combined analysis of The
Netherlands I, The Netherlands II and Spain cohorts were
selected for a validation step (table 2).
In the validation phase, a combined analysis of the previously
selected SNPs using the inverse variance method under a ﬁxed
effects model was performed using the association results of the
three analysed populations and the ACPA− RA patients and con-
trols of the Swedish cohort in Padyukov et al.13 A p value
<5×10−6 was established as arbitrary threshold to consider a
SNP as a suggestive association in the meta-analysis.
Additionally, loci showing a high heterogeneity (Q<0.05) were
discarded.
For the analysis of the imputed data in the HLA region, we
performed the association analyses by means of unconditional
and conditional logistic regression analysis to account for
dependency between the observed signals (details in online sup-
plementary note 3). Finally, we searched recursively for models
which better explained all association present in the HLA region
(see online supplementary note 3).
Regional plots were generated using LocusZoom, and the
remaining ﬁgures were generated using R V.2.15.1.26 27
RESULTS
Independent and combined analyses of three European
ACPA− populations
Independent analysis of The Netherlands I, The Netherlands II
and Spain cohorts showed no associations at genome-wide sig-
niﬁcance level (p<5×10−8) (see online supplementary ﬁgures
S2–S4). However, the combined analysis of the three cohorts
identiﬁed a SNP in the CLYBL locus and two in SMIM21
showing signiﬁcant risk associations at this level (ﬁgure 2).
Moreover, 47 variants in 34 non-HLA loci showed a suggestive
p value <5×10−5 and no heterogeneity, and were selected for
follow-up (table 2 and ﬁgure 3). Additionally, the combined ana-
lysis of the three cohorts resulted in a peak of association in the
HLA region in chromosome 6.
HLA region deep interrogation
We further explored the association in the HLA region applying
a new imputation method, which inferred the classical HLA
alleles, polymorphic amino acid positions and SNPs in the
studied populations.21 22 After imputation, the most signiﬁcant
association corresponded with amino acid position 67 of the
HLA-DRβ1 molecule (p = 4.13×10−9, see online supplemen-
tary table S3). Three amino acids in this HLA-DRβ1 position
were observed in our population (leucine, Leu; isoleucine, Ile;
phenylalanine, Phe), but only the Leu67 variant showed
genome-wide association (p=9.41×10−10. Furthermore, three
additional amino acid residues showed a genome-wide level sig-
niﬁcant association in our study: two located in the HLA-DRB1
gene (the presence of threonine in the 181 amino acid position,
Thr181, p value = 2.74×10−8, and the combination of serine,
Ser, valine, Val and leucine, Leu, in the position 11,
SerValLeu11, p value = 4.27×10−8) and one in the HLA-B
locus (the presence of aspartic acid in the ninth position, Asp9,
p value = 9.27×10−9). Moreover, these residues corresponded
with the most associated amino acid positions in the omnibus
test (see online supplementary note 3 and table S3). Then, we
hypothesised that the association in the HLA region might be
explained by polymorphic amino acid residues in the HLA
molecules as observed in previous reports.14 21 22
Therefore, we performed step-wise conditional regression
analysis including each of the four amino acid positions that had
an amino acid residue reaching genome-wide level association.
These analyses identiﬁed two independent signals among the
selected amino acid positions: HLA-B at position 9 and
HLA-DRB1 at position 11(see online supplementary table S4).
After controlling for the two previously mentioned associations,
no signal showing a p<5×10−5 remained in the HLA region
(ﬁgure 4).
Additionally, we observed that the HLA-B*0801 allele was
the only classical HLA allele associated at genome-wide level in
our study. However, this allele was indistinguishable from the
HLA-B Asp9 variant using conditional logistic regression, due to
their high linkage disequilibrium (r2=0.996). Regarding the
HLA-DRB1 independent position, several classical HLA alleles
share the genome-wide associated amino acid residues (see
online supplementary note 5). Additionally, we conﬁrmed that
the hypothesis-free model was equivalent to the amino acid
model, and addition of each amino acid variant to our model
outperformed the model without it and achieved a better
Table 1 Study design
Population GWAS genotyping platform (ACPA−/CTRL)
N ACPA−/CTRL after
PCA and QC
Genotyped SNPs
after QC
Imputed SNPs
after QC
The
Netherlands I
Illumina HumanCytoSNP-12BeadChip/Illumina Infinum HumanHap550
BeadChip
672/2323 86 120 605 112
The
Netherlands II
Illumina HumanCytoSNP-12BeadChip/ Illumina HumanCytoSNP-12BeadChip 118/3264 254 132 757 513
Spain Illumina HumanCytoSNP-12BeadChip/Illumina HumanCytoSNP-12BeadChip
+Illumina Human CNV370 K BeadChip
358/421 85 978 473 710
CTRL, control; GWAS, genome-wide association study; PCA, principal component analysis; QC, quality control; SNP, single nucleotide polymorphism.
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Table 2 Non-HLA SNPs associated with p value <5E-05 in the combined analysis of The Netherlands I, The Netherlands II and Spain populations
Spain The Netherlands I The Netherlands II Combined
Chr position
(bp) SNP Locus P OR (CI)
MAF ACPA
−/CTRL P OR (CI)
MAF ACPA
−/CTRL P OR (CI)
MAF ACPA
−/CTRL PinvVar OR Q
1 (58 814 769) rs14008 TACSTD2* 1.43E-02 0.43 (0.22–0.85) 0.02/0.05 1.90E-05 0.50 (0.36–0.69) 0.04/0.07 0.95 0.98 (0.53–1.83) 0.05/0.05 7.40E-06 0.55 0.12
1 (81 205 529) rs6684037 LPHN2 0.10 0.66 (0.40–1.09) 0.04/0.06 1.17E-04 0.51 (0.36–0.72) 0.03/0.07 0.41 0.72 (0.34–1.55) 0.03/0.04 3.70E-05 0.57 0.56
1 (151 350 870) rs383582 SPRR2F 0.49 1.13 (0.80–1.60) 0.11/0.09 6.00E-06 1.63 (1.32–2.01) 0.13/0.09 0.40 1.19 (0.79–1.79) 0.11/0.10 2.52E-05 1.42 0.14
2 (234 061 305) rs10929178 USP40 0.20 1.24 (0.89–1.71) 0.13/0.10 5.62E-05 1.51 (1.24–1.84) 0.14/0.10 0.46 1.17 (0.78–1.74) 0.11/0.10 4.80E-05 1.39 0.39
3 (55 865 516) rs7609626 ERC2 4.22E-04 0.44 (0.28–0.70) 0.04/0.10 1.05E-03 0.60 (0.45–0.82) 0.05/0.08 0.30 0.68 (0.33–1.39) 0.04/0.05 1.91E-06 0.56 0.45
3 (64 112 733) rs929701 PRICKLE2 0.11 1.34 (0.93–1.93) 0.11/0.09 7.71E-04 1.43 (1.16–1.76) 0.13/0.10 0.06 1.44 (0.99–2.11) 0.14/0.11 3.23E-05 1.42 0.95
3 (65 270 367) rs13100540 ADAMTS9-AS2—MAGI1 0.23 1.15 (0.91–1.45) 0.33/0.30 6.70E-05 1.33 (1.15–1.52) 0.38/0.33 0.19 1.20 (0.92–1.57) 0.39/0.35 2.41E-05 1.26 0.54
3 (106 853 033) rs9857831 ALCAM—CBLB 1.10E-02 1.36 (1.07–1.72) 0.36/0.31 1.64E-02 1.19 (1.03–1.36) 0.37/0.33 1.07E-02 1.42 (1.08–1.85) 0.42/0.34 3.94E-05 1.26 0.40
4 (102 253 020) rs2732512 PPP3CA 0.12 1.42 (0.91–2.23) 0.07/0.05 1.26E-02 1.47 (1.09–2.00) 0.05/0.04 1.72E-03 2.09 (1.32–3.31) 0.09/0.05 4.67E-05 1.58 0.40
5 (126 163 281) rs17598783 LMNB1* 0.29 1.13 (0.90–1.42) 0.33/0.31 1.89E-03 1.24 (1.08–1.43) 0.36/0.32 2.61E-03 1.50 (1.15–1.96) 0.42/0.32 3.32E-05 1.26 0.27
5 (165 080 723) rs12657428 TENM2 9.32E-04 2.49 (1.45–4.27) 0.06/0.03 7.16E-04 1.77 (1.27–2.45) 0.05/0.03 0.92 1.03 (0.57–1.86) 0.05/0.05 2.61E-05 1.72 0.09
7 (9 537 527) rs6463923 NXPH1* 0.13 0.84 (0.68–1.05) 0.35/0.36 1.36E-06 0.71 (0.62–0.82) 0.33/0.41 0.35 0.88 (0.67–1.16) 0.36/0.39 1.14E-06 0.77 0.25
7 (19 498 740) rs10216141 TWISTNB 5.34E-03 2.29 (1.28–4.11) 0.05/0.02 3.57E-02 1.48 (1.03–2.13) 0.04/0.02 1.13E-02 2.06 (1.18–3.60) 0.06/0.03 4.53E-05 1.76 0.38
7 (108 372 672) rs848324 THAP5 3.67E-03 0.44 (0.25–0.77) 0.03/0.07 5.25E-04 0.55 (0.39–0.77) 0.04/0.06 0.99 0.99 (0.52–1.89) 0.04/0.04 4.29E-05 0.58 0.16
7 (140 342 281) rs38723 BRAF-MRPS33* 2.78E-03 0.42 (0.24–0.74) 0.03/0.06 2.70E-05 0.48 (0.34–0.68) 0.03/0.07 0.22 0.64 (0.31–1.31) 0.03/0.05 1.77E-07 0.49 0.67
7 (140 426 209) rs557962 Transmembrane protein
178-like
1.14E-04 0.40 (0.25–0.64) 0.04/0.09 2.19E-03 0.66 (0.50–0.86) 0.06/0.09 0.50 0.83 (0.49–1.42) 0.06/0.07 7.87E-06 0.61 0.09
8 (18 286 035) rs17642674 NAT1—NAT2 0.07 1.35 (0.98–1.86) 0.14/0.10 3.61E-03 1.35 (1.10–1.65) 0.13/0.10 1.16E-02 1.59 (1.11–2.27) 0.16/0.11 2.90E-05 1.39 0.72
9 (120 110 400) rs7047525 TLR4* 3.25E-02 0.72 (0.54–0.97) 0.15/0.18 1.99E-04 0.67 (0.54–0.83) 0.10/0.15 0.12 0.68 (0.42–1.11) 0.08/0.12 5.70E-06 0.69 0.92
10 (69 579 808) rs10997948 MYPN* 3.75E-02 1.57 (1.03–2.40) 0.08/0.05 3.46E-05 1.64 (1.30–2.07) 0.10/0.07 0.10 1.41 (0.93–2.14) 0.11/0.08 1.07E-06 1.58 0.83
10 (72 178 560) rs7921298 ADAMTS14 2.98E-02 0.52 (0.29–0.94) 0.03/0.05 5.21E-04 0.55 (0.40–0.77) 0.04/0.06 0.13 0.50 (0.21–1.24) 0.02/0.04 1.35E-05 0.54 0.97
10 (84 025 408) rs4329625 NRG3 8.90E-04 2.58 (1.48–4.52) 0.06/0.03 3.88E-04 1.96 (1.35–2.84) 0.04/0.02 0.11 1.63 (0.89–3.00) 0.05/0.03 6.10E-07 2.02 0.54
11 (60 123 089) rs7927817 MS4A13—MR_026 946.1 0.10 1.36 (0.95–1.95) 0.11/0.09 1.39E-05 1.52 (1.26–1.83) 0.16/0.11 0.96 0.99 (0.68–1.45) 0.13/0.13 2.48E-05 1.39 0.14
11 (63,641,881) rs3824854 FLRT1 4.71E-02 1.29 (1.00–1.66) 0.26/0.22 4.62E-03 1.29 (1.08–1.53) 0.19/0.16 2.10E-02 1.46 (1.06–2.02) 0.21/0.15 4.18E-05 1.32 0.78
11 (88,307,788) rs518167 GRM5 9.12E-03 2.55 (1.26–5.14) 0.04/0.02 5.66E-04 2.22 (1.41–3.49) 0.03/0.01 0.21 1.66 (0.75–3.66) 0.03/0.02 9.68E-06 2.17 0.72
12 (78,361,110) rs7959721 SYT1 0.97 1.01 (0.48–2.13) 0.02/0.02 1.53E-06 2.55 (1.74–3.74) 0.04/0.02 0.39 1.34 (0.68–2.65) 0.04/0.03 2.50E-05 1.92 0.05
13 (50 474 171) rs3790022 RNASEH2B-FAM124A 1.19E-03 0.51 (0.34–0.77) 0.06/0.10 4.60E-04 0.62 (0.48–0.81) 0.06/0.08 0.08 0.53 (0.26–1.08) 0.03/0.06 5.56E-07 0.58 0.69
13 (99 319 102) rs9557321 CLYBL 0.08 1.62 (0.94–2.77) 0.05/0.04 4.33E-07 2.08 (1.57–2.77) 0.07/0.04 0.07 1.48 (0.97–2.28) 0.11/0.08 4.51E-08 1.83 0.38
16 (60 319 776) rs16963882 CDH8 4.36E-02 0.71 (0.51–0.99) 0.10/0.14 9.02E-05 0.67 (0.55–0.82) 0.12/0.16 0.80 0.95 (0.64–1.41) 0.13/0.14 3.62E-05 0.72 0.30
17 (23 876 812) rs598858 FOXN1 0.22 1.42 (0.81–2.50) 0.05/0.03 2.45E-05 1.85 (1.39–2.47) 0.07/0.04 0.10 1.49 (0.93–2.37) 0.08/0.06 4.50E-06 1.69 0.59
17 (43 952 192) rs11651168 SKAP1—HOXB1* 3.07E-02 0.79 (0.64–0.98) 0.44/0.50 5.45E-04 0.79 (0.69–0.90) 0.45/0.51 0.14 0.82 (0.63–1.07) 0.42/0.48 1.46E-05 0.80 0.98
18 (71 591 842) rs1943199 SMIM21* 2.01E-03 2.84 (1.47–5.51) 0.05/0.02 1.54E-07 2.66 (1.85–3.84) 0.05/0.02 0.12 1.53 (0.90–2.61) 0.07/0.05 1.73E-09 2.33 0.20
19 (57 624 232) rs8182486 ZNF534 2.52E-02 1.58 (1.06–2.36) 0.10/0.06 3.44E-04 1.62 (1.25–2.12) 0.07/0.05 0.45 1.20 (0.75–1.91) 0.08/0.07 3.49E-05 1.53 0.53
20 (51 981 774) rs6013838 BCAS1 0.09 0.55 (0.27–1.11) 0.02/0.04 7.71E-05 0.40 (0.26–0.63) 0.02/0.04 0.51 0.68 (0.21–2.17) 0.01/0.02 2.33E-05 0.46 0.61
22 (21 946 433) rs12166802 BCR (Breakpoint Cluster
Region)
5.48E-03 2.18 (1.26–3.78) 0.06/0.03 2.60E-03 1.62 (1.18–2.22) 0.05/0.04 0.30 1.39 (0.74–2.60) 0.05/0.03 4.66E-05 1.68 0.53
Controls are used as reference for all comparisons.
The genome-wide significant p value is shown in bold.
CTRL, control; MAF, minor allele frequency; OR, OR for the minor allele; p, logistic regression p value including 10 PC as covariates; PInvVar, inverse variance fixed effects combined-analysis p value; Q, Cochran Q test p value.
*Multiple signals fulfilling the selection criteria in the locus, the reported variant corresponds with the most strongly associated polymorphism.
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goodness-of-ﬁt (table 3 and see online supplementary note 3).
We also conﬁrmed that the model including the two independ-
ent amino acid variants was the most parsimonious explanation
for our data, and the addition of the remaining amino acids did
not lead to a better goodness-of-ﬁt (table 3).
Follow-up meta-analysis
After imputation, 363 330variants were shared among all three
previously described European populations and the Swedish
cohort described in Padyukov et al.13 The ﬁnal set of 452 367
SNPs analysed in our cohorts tagged (with r2>0.8) a 52.37% of
the SNPs with MAF>0.05 included in the HapMap phase 3
Caucasian of EUropean Ancestry (CEU) population and 51.63%
of the SNPs in the CEU/Tuscans in Italy (TSI) populations (fol-
lowing the same parameters). As it can be observed in ﬁgure 5
and table 4, the variant in CLYB that previously showed genome-
wide level association (rs9557321) did not reach the genome-
wide signiﬁcance threshold after meta-analysis but maintained a
suggestive association (p value=5.82×10−8 OR=1.73). In the
case of the genome-wide level associations in the SMIM21 locus
(rs1943199, rs11663465), signiﬁcant heterogeneity was found in
the meta-analyses (Q<0.05) and the SNPs were discarded from
analysis. Additionally, 30 out of 34 loci selected for the follow-up
phase were shared between the genotyped and the Swedish popu-
lations, and two of them, CLYBL and SMIM21, were still signiﬁ-
cant considering a p value <5×10−6 in the meta-analysis (ﬁgure
3, regional plots are given in ﬁgure 2). The variants showing tier
2 associations were rs518167 (located in the 2nd intron of the
GRM5 gene) and rs3790022 (located in the RNASEH2B-
FAM124A intergenic region, ie, GUCY1B2 pseudogene) (table 4
and see online supplementary table S5).
Regarding the HLA region, no classical HLA allele informa-
tion was available for the Swedish cohort, and unfortunately,
our two-variant models could not be tested in this cohort.
Nevertheless, the genome-wide associated variant in the HLA
class I region, rs2596565, was included in the combined ana-
lysis, showed nominal association in the Swedish cohort
(p=2.12×10−2 OR=1.24) and was the only SNP showing
genome-wide signiﬁcance in the HLA region (p=9.26×10−9
OR=1.4) (ﬁgure 6).
Figure 2 Regional association plots
showing (A) the CLYBL locus (B) the
SMIM21 locus.
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Five out of 7 loci previously associated with ACPA− RA by
Viatte et al12 were properly covered in our study (directly
included or tagged by a variant showing r2>0.8). For these loci,
we observed trends of association (p<0.05) in the TNFAIP3,
GIN1/C5orf30 and PTPN22 loci (see online supplementary
table S6). In the case of the HLA-DRB1* 04 : 01 tag-SNP, a
trend association was observed, but the meta-analysis showed
signiﬁcant heterogeneity. Thus, we applied a random effects
model and the initial association was lost (see online supplemen-
tary table S6).
The previously reported variant of CLEC16A (rs6498169)
was ﬁltered out from the current analyses during QC, but the
most strongly associated variant located in the gene showed a
nominal association in the combined analysis (rs17803698
p=2.12×10−2 OR=1.14, r2=0.12).15 In the case of
TNPO3-IRF5 region, we selected variants from Viatte et al12
and Sigurdsson et al16 that were included in the combined ana-
lysis. The rs12531711 showed a remarkably strong association
with ACPA− RA in the combined analysis (p=4.35×10−5
OR=1.30).
DISCUSSION
This report comprises the largest ACPA− RA cohort genotyped
and analysed with a genome-wide platform to date (1922 ACPA
− RA patients and 7087 non-affected controls). Our study iden-
tiﬁed a suggestive new risk factor for this condition, (CLYBL),
conﬁrmed the association of the HLA region with this subset
and proposed a two-variant model including the HLA-DRB1
and HLA-B loci to explain the observed HLA association peak.
The ﬁrst GWAS that focused on the ACPA+ versus ACPA−
genetic differences did not show evidence for an association of
ACPA− RA with the HLA region in a cohort of Swedish RA
patients.13 Nevertheless, recent reports have suggested a previ-
ously unidentiﬁed role for the HLA region.12 14 Taking into
account that the Immunochip platform includes a dense
mapping of the HLA region, and that the cohorts analysed in
the present study are partially overlapping with the populations
in Eyre et al, we consider that the resemblance of the results in
genome-wide and Immunochip platforms conﬁrm previous ﬁnd-
ings, and indicate that the coverage of the HLA region in our
study was appropriate.14 Moreover, in Eyre et al, the ﬁve-amino
acid model which was described by Raychaudhuri et al21 and
accounted for the observed association in the HLA region was
conﬁrmed.14 Nevertheless, this novel HLA allele and amino
acid residue imputation approach was not applied separately in
the ACPA− group. In our ACPA− study, we used this approach
to detect two-amino acid position (HLA-B at position 9 and
HLA-DRB1 at position 11), as the most parsimonious model
explaining the observed association in the HLA region in our
data. The two of the identiﬁed amino acid position, HLA-DRB1
11th amino acid and HLA-B 9th amino acid, were located in
the peptide binding groove of their corresponding HLA mole-
cules.21 Moreover, both amino acid positions were shared
between our model and the ACPA+ RA model proposed by
Raychaudhuri et al21 and conﬁrmed by Eyre et al14 However,
no signiﬁcant association was found for the SE variants or other
ACPA+-related HLA-DRB1 amino acid positions (HLA-.DRB1
13, 71 and 74 positions), which can be due to real association
divergences in these subgroups. Moreover, given the observed
association of HLA-B, it can be hypothesised that HLA class
I has a more relevant role in ACPA− RA than in ACPA+ RA,
while the HLA class II association seems more predominant
ACPA+ RA. However, the partial overlap and the differences
between the proposed HLA models for both RA serological sub-
groups would require further studies to clarify if the
HLA-DRB1 and HLA-B signals belong to both RA subgroups or
are restricted to ACPA+ or ACPA−, respectively. Additionally,
individuals showing borderline ACPA titres and seroconversion
from negative to positive ACPA is a rare event (only 2%), but it
may act as a confounding factor.28
In relation to the novel candidate association with a SNP in
the CLYBL gene, although the signal is slightly below the
genome-wide signiﬁcance level, our ﬁndings might support
future studies to clarify the veracity of this association. CLYBL
Figure 3 Manhattan plot of the genome-wide association study (GWAS) of the three European cohorts comprising 1148 anti-citrullinated peptide
antibodies-Rheumatoid arthritis (ACPA- RA) cases and 6008 healthy controls (The Netherlands I, The Netherlands II and Spanish populations). The
−log10 of the inverse variance test p value of 452 367 SNPs is plotted against its physical chromosomal position. Chromosomes are shown in
alternate colours. SNPs above the red line represent those with a p value <5×10−8 and variants in GWAS level loci are shown in orange.
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encodes a citrate lyase subunit β-like protein which has citrate
(pro-3S)-lyase and ion-binding activities that are transported to
the mitochondria. Interestingly, a SNP in the CLYBL locus has
been recently associated with low serum levels of vitamin B12
(also known as cyanocobalamin).29 30 Although the relation
between CLYBL and the vitamin B12 serum levels remains
Figure 4 Manhattan plots showing
the results of the unconditioned and
conditioned analyses of the imputed
HLA region. (A) Unconditioned analysis
of the HLA region. (B) Conditional
analysis controlling for the
independent association of the 9th
amino acid position at HLA-B.
(C) Conditional analysis controlling for
the previously mentioned association
in the 9th amino acid position at
HLA-B and the independent
association of the 11th amino acid
position at HLA-DRB1.
Table 3 Comparison of goodness-of-fit of the different amino acid position models for the HLA region
Model χ2 Dif p value 2Df
HLA-B 9th position NA
HLA-B 9th position +HLA-DRB1 11th 42.5 4.80E-08 5.9053E-10
HLA-B 9th position +HLA-DRB1 11th position+HLA-DRB1 67th position 7.28 0.06 0.03
HLA-B 9th position+HLA-DRB1 11th position+HLA-DRB1 181st position 8.24 0.04 0.02
HLA-B 9th position +HLA-DRB1 11th position+HLA-DRB1 67th position+HLA-DRB1 181st position 10.74 0.06 0.005
rs3132510+HLA-DRB1 11th position 0.39 0.82 0.66
The goodness-of-fit for each model was compared with the previous one. Best fitting model in bold.
χ2 Dif, improvement in the goodness of fit (by calculating the deviance, defined as −2 × the log likelihood, and following a χ2 distribution of the model compared with the preceding
one; p value, p value for the model comparison.
*Comparison between the hypothesis free model and the amino acid model.
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unclear, a link between vitamin B12 and RA has been described.
In a report by Regal et al, 24% of RA patients had low vitamin
B12 serum levels and 26% of them had true vitamin B12 deﬁ-
ciency.31 Besides, a previous study described that RA patients
with vitamin B12 deﬁciency, folate deﬁciency, vitamin B6 deﬁ-
ciency and impaired renal function showed associated hyperho-
mocysteinemia that may have a role in promoting high
cardiovascular morbidity in patients with RA.32 Moreover, sig-
niﬁcant associations with the familial risk of RA in offspring
according to parental proband were reported for pernicious
anaemia, which is usually the result of intrinsic factor insufﬁ-
cient secretion and consequent vitamin B12 deﬁciency.33
Additionally, the design of our study led to some limitations
mainly due to the variety of genotyping platforms used.
Figure 5 Manhattan plot showing the meta-analysis comprising 1922 cases and 7087 controls from all the studied populations (The Netherlands
I, The Netherlands II, Spain and Sweden populations). The −log10 of the inverse variance test p value of 363 330 SNPs is plotted against its
physical chromosomal position. Chromosomes are shown in alternate colours. SNPs above the red line represent those with a p value <5×10−8 and
variants in genome-wide association study level loci are shown in orange.
Table 4 Previously selected non-HLA SNPs showing a p value <5×10−6 and HLA SNPs showing a p value <5×10−7 in the inverse variance
meta-analysis of all the cohorts included the study
CHR BP SNP Locus P InvVar OR Q
Non-HLA loci 11 88 307 788 rs518167 GRM5 1.84E-06 2.24 0.74
13 50 474 171 rs3790022 RNASEH2B-FAM124A 1.36E-06 0.67 0.18
13 99 319 102 rs9557321 CLYBL 5.82E-08 1.73 0.32
HLA loci 6 31 202 682 rs3130557 PSOR1C1 3.33E-07 1.35 0.36
6 31 443 433 rs2844573 HLA-B/MICA 3.88E-07 1.25 0.59
6 31 456 056 rs9266669 HLA-B/MICA 2.27E-07 1.34 0.41
6 31 461 308 rs2596565 HLA-B/MICA 9.26E-09 1.4 0.17
6 31 542 600 rs3131618 MICA/MICB 8.63E-08 1.39 0.19
6 31 573 026 rs3094005 MICA/MICB 4.61E-07 1.35 0.26
6 31 613 459 rs2734583 DDX39B 4.46E-07 1.35 0.28
6 31 820 175 rs3132445 MSH5 3.79E-07 1.36 0.06
6 31 823 861 rs3130484 MSH5 3.89E-07 1.36 0.06
6 31 829 012 rs3131379 MSH5 3.05E-07 1.37 0.06
6 31 833 209 rs3117574 MSH5 3.80E-07 1.36 0.06
6 31 833 264 rs3131378 MSH5 3.90E-07 1.36 0.06
6 31 834 232 rs3117575 MSH5 3.96E-07 1.36 0.06
6 31 835 453 rs3117577 MSH5 3.89E-07 1.36 0.07
6 31 835 876 rs3115672 MSH5 4.22E-07 1.36 0.07
6 31 915 519 rs3130679 C6orf48 4.57E-07 1.36 0.06
6 31 986 412 rs519417 C2 8.67E-08 1.38 0.06
6 32 000 463 rs497309 C2 1.44E-07 1.37 0.06
6 32 048 876 rs389884 STK9 8.32E-08 1.39 0.05
6 32 167 845 rs1150753 TNXB 1.77E-07 1.38 0.05
6 32 691 720 rs9271348 HLA-DRB1/HLA-DQA1 4.79E-07 0.78 0.31
Controls are used as reference for all comparisons.
PInvVar, inverse variance fixed effects combined-analysis p value; OR, OR for the minor allele; Q, Cochran Q test p value.
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Therefore, some associations might have been overlooked due
to a limited coverage in the region despite the imputation step
(ie, the ANKRD55/IL6ST locus). In spite of the large size of the
ACPA− patient cohort, our study might have been underpow-
ered to detect modest associations. Additionally, our conclusions
may be applicable only in populations of European ancestry.
The present report analysed the genetic component of a large
cohort of ACPA− RA patients compared to non-affected con-
trols following a genome-wide strategy, replicated previous ﬁnd-
ings in different non-HLA loci, such as TNFAIP3, GIN1/
C5orf30, PTPN22, CLEC16A and TNPO3/IRF5, and revealed a
novel suggestive susceptibility gene, CLYBL. Moreover, our
study provided a deep insight into the inﬂuence of the HLA
region in ACPA− RA and identiﬁed a two-amino acid residue
model explaining this association. The present study together
with previous evidence supported the existence of an
ACPA-speciﬁc genetic component, and highlighted the import-
ance of comprehensive genetic analysis of large ACPA− cohorts.
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